Geron Corporation
149 Commonwealth Drive
Menlo Park
California
94025
United States
Tel: 650-473-7700
Fax: 650-473-7750
Website: http://www.geron.com/
Email: info@geron.com
466 articles about Geron Corporation
-
Despite skepticism from FDA reviewers, the Oncologic Drugs Advisory Committee on Thursday strongly supported Geron’s imetelstat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.
-
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
3/14/2024
Geron Corporation announced that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.
-
In a briefing document for Thursday’s advisory committee meeting, the FDA pointed to efficacy and safety issues with Geron’s New Drug Application for imetelstat in myelodysplastic syndromes.
-
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2/28/2024
Geron Corporation today reported business highlights and financial results for the fourth quarter and full year 2023.
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 22, 2024
2/22/2024
Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 397,010 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2024
1/18/2024
Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 895,930 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 21, 2023
12/21/2023
Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 417,490 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
-
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
12/11/2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial evaluating first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS), as well as population analysis of claims data in lower risk MDS.
-
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
12/6/2023
Geron Corporation today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF).
-
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
12/4/2023
Geron Corporation announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes relapsed/refractory or ineligible for erythropoiesis stimulating agents.
-
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
11/28/2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors.
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 16, 2023
11/16/2023
Geron Corporation, a late-stage clinical biopharmaceutical company, reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
-
Geron to Participate at Upcoming Investor Conferences in November 2023
11/7/2023
Geron Corporation, a late-stage clinical biopharmaceutical company, announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences.
-
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
11/2/2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of abstracts from the IMerge Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat in patients with lower risk myelodysplastic syndromes (MDS).
-
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
11/2/2023
Geron Corporation today reported business highlights and financial results for the third quarter of 2023.
-
Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023
10/26/2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its third quarter 2023 financial results and business highlights before the market opens on Thursday, November 2, 2023 via press release, which will be available on the Company’s website at www.geron.com/investors.
-
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 19, 2023
10/19/2023
Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 401,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
-
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
9/29/2023
Geron Corporation (Nasdaq: GERN) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).
-
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
9/11/2023
Geron Corporation, a late-stage clinical biopharmaceutical company, announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, effective September 25, 2023.
-
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
9/7/2023
Geron Corporation (Nasdaq: GERN) today announced poster presentations of data from IMerge, the Company’s Phase 3 clinical trial evaluating its first-in-class investigational telomerase inhibitor imetelstat vs. placebo in patients with lower risk myelodysplastic syndromes (MDS) at the eleventh annual Society of Hematologic Oncology Annual Meeting (SOHO) held in Houston, Texas and virtually.